In the Aggrenox case, Faruqi & Faruqi represents a pharmaceutical wholesaler and a proposed class of direct purchasers of Boehringer Ingelheim’s combination stroke prevention drug, Aggrenox. The case alleges that Boehringer paid its would-be generic competitors (Duramed, later known as Barr, and still later known as Teva) to delay launching their less-expensive generic versions of Aggrenox, in what is known as a “pay for delay” conspiracy. The case settled for $146 million in late 2017.
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Filed on 12/02/2013
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771
Joseph T. Lukens email@example.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn firstname.lastname@example.org Phone (215) 277-5770 Fax (215) 277-5771